SUMMIT, N.J., Sept. 22, 2014 – In recognition of his innovative contributions to the education and advancement of bovine veterinary students and the dairy industry, Merck Animal Health and the American Association of Bovine Practitioners (AABP) presented John Fetrow, D.V.M., with the Mentor of the Year Award at this year’s AABP Annual Conference.
The annual award honors an individual who has dedicated his or her career to educating, mentoring and advancing the careers of bovine veterinary medical students. Dr. Fetrow was honored with a commemorative plaque and will receive an all-expenses-paid trip to next year’s AABP conference.
“Dr. Fetrow’s scientific contributions to veterinary medicine and his ongoing work as a student mentor are remarkable and deserving of recognition,” said Norman Stewart, D.V.M., livestock technical services manager for Merck Animal Health. “We commend his dedication and ability to inspire students across the globe, as well as the honor and integrity he demonstrates to his students every day.”
Dr. Fetrow has been a mentor to innumerable veterinary students, colleagues and food animal producers. “Being a mentor is similar to investing in that the return or recognition often comes years or even decades after the fact,” said M. Gatz Riddell Jr., D.V.M., executive vice president of the AABP. “Many mentees are not even aware of the process at the time and only years later realize the impact a mentor had on their life and career. This is why John and other lifetime mentors like him are so worthy of this level of recognition.”
Most notable among Dr. Fetrow’s long list of contributions in his 36-year career is the creation and implementation of the Transition Management Facility associated with the University of Minnesota College of Veterinary Medicine (UMCVM). Initiated in the late 1990s, the project was the nation’s first private-public partnership to provide veterinary students with a two-week clinical training rotation on a commercial dairy operation.
“It was an excellent, cost-effective, innovative model to provide hands-on training to our professional veterinary students, but also for continuing education programs for veterinarians and producers,” said Sandra Godden, D.V.M., dairy veterinary science professor, University of Minnesota, who nominated Dr. Fetrow for the award.
In 2007, Dr. Fetrow secured funding for and designed new facilities to expand and move the program to a 7,000-cow dairy in South Central Minnesota that included a large cheese processing plant. Today, the UMCVM Dairy Education Center includes classrooms, a research laboratory and a dormitory. In 2011, a federal grant allowed Dr. Fetrow to expand yet again and develop the Center of Excellence in Dairy Production Medicine Education, which added the University of Illinois, Kansas State University and the University of Georgia to the roster. This effort allowed for the creation of an eight-week advanced program for senior veterinary graduates entering careers in dairy production medicine.
Driven by his exceptional vision for teaching what is important and by employing novel approaches that have changed the way things are done in the classroom and on the farm, Dr. Fetrow has had an unparalleled impact on the teaching, learning and practice of dairy production medicine in North America and around the world,” said Ken Leslie, D.V.M., Professor Emeritus, Department of Population Medicine, Ontario Veterinary College, University of Guelph, who wrote a letter of support for the nomination of Dr. Fetrow.
Joining the University of Minnesota in 1991, Dr. Fetrow is today a Professor of Dairy Production Medicine in the university’s Department of Veterinary Population Medicine. He also is a special graduate faculty member in the Department of Population Medicine at the Ontario Veterinary College, University of Guelph. He received his Doctor of Veterinary Medicine degree from the University of Pennsylvania and a Master of Business Administration from the Wharton School of Business.
Dr. Fetrow has received numerous honors throughout his career, including the inaugural AABP Distinguished Service Award. He is the eighth recipient of the Mentor of the Year Award, which was instituted in 2007.
About Merck Animal Health
Today’s Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn and Twitter at @MerckAH.
Merck Forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2013 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).